Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Oncologists hesitant to prescribe biosimilar MAbs

    • 24 Accesses

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Oncologists hesitant to prescribe biosimilar MAbs. Pharmacoecon. Outcomes News 666, 5 (2012). https://doi.org/10.2165/00151234-201206660-00013

    Download citation

    Keywords

    • Monoclonal Antibody
    • Health Outcome
    • Research Group
    • Bevacizumab
    • Trastuzumab